Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aldeyra Therapeu (NQ: ALDX )

6.770 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15
Open 6.770
Bid (Size) 5.420 (2)
Ask (Size) 7.030 (1)
Prev. Close 6.770
Today's Range 6.770 - 6.770
52wk Range 2.355 - 7.990
Shares Outstanding 58,560,078
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for ADX‑2191 for the Treatment of Primary Vitreoretinal Lymphoma
From Aldeyra Therapeutics, Inc.
Via Business Wire

Performance

YTD
-2.73%
-2.73%
1 Month
+6.28%
+6.28%
3 Month
+24.91%
+24.91%
6 Month
-9.13%
-9.13%
1 Year
+84.97%
+84.97%

More News

Read More
Aldeyra Therapeutics' RASP Modulator Shows Improved Signs of Alcohol Intoxication
Via Benzinga
Aldeyra's ADX-2191 Aces Late-Stage Study In Rare Vision Disorder
Via Benzinga
Recap: Aldeyra Therapeutics Q2 Earnings
Via Benzinga
Aldeyra Therapeutics’ Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Reports Third-Quarter 2022 Financial Results and Recent Corporate Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Announces Oral Presentation of Phase 3 Data at the American Academy of Optometry 2022 Annual Meeting
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Achieves Primary Endpoint in Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
From Aldeyra Therapeutics, Inc.
Via Business Wire
Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary
Via Benzinga
Aldeyra Therapeutics Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA and Highlights Upcoming Corporate Milestones
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics to Participate in Upcoming Investor Conferences
From Aldeyra Therapeutics, Inc.
Via Business Wire
$2 Million Bet On This Industrial Stock? 4 Stocks Insiders Are Buying
Via Benzinga
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
Via Benzinga
Aldeyra Therapeutics Reports Second-Quarter 2022 Financial Results and Recent Corporate Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For August 5, 2022
Via Benzinga
Earnings Outlook For Aldeyra Therapeutics
Via Benzinga
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
The Daily Biotech Pulse: GSK To Supply 50M Flu Vaccine Doses To US, FDA Lifts Hold On Greenwich's Cancer Immunotherapy Trial, Connect Biopharma Sees CBP-201 Topline Data Sooner
Via Benzinga
Boeing, PriceSmart And 80 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.